TG Therapeutics
is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.
Product Pipeline
Ublituximab is a novel, third-generation monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.
TGR-1202 is a highly specific, orally available, PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.
For Investors
Stock Quote at: May 21, 1:46PM EDT
News & Events
5.13.13
TG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business Update
4.29.13
TG Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare Conference
Quick Links
